A detailed history of Wells Fargo & Company transactions in Abeona Therapeutics Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 60 shares of ABEO stock, worth $342. This represents 0.0% of its overall portfolio holdings.

Number of Shares
60
Previous 60 -0.0%
Holding current value
$342
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$3.17 - $8.05 $583 - $1,481
-184 Reduced 75.41%
60 $0
Q1 2024

May 10, 2024

BUY
$4.07 - $8.68 $28 - $60
7 Added 2.95%
244 $1,000
Q4 2023

Feb 09, 2024

BUY
$3.71 - $5.14 $255 - $354
69 Added 41.07%
237 $1,000
Q3 2023

Nov 13, 2023

BUY
$2.98 - $4.43 $119 - $177
40 Added 31.25%
168 $0
Q2 2023

Aug 15, 2023

BUY
$2.76 - $5.27 $41 - $79
15 Added 13.27%
128 $0
Q1 2023

May 12, 2023

BUY
$2.25 - $3.27 $144 - $209
64 Added 130.61%
113 $0
Q4 2022

Feb 13, 2023

BUY
$2.4 - $5.65 $33 - $79
14 Added 40.0%
49 $0
Q3 2022

Nov 14, 2022

BUY
$2.79 - $5.56 $97 - $194
35 New
35 $0

Others Institutions Holding ABEO

About ABEONA THERAPEUTICS INC.


  • Ticker ABEO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 5,950,380
  • Market Cap $33.9M
  • Description
  • Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-a...
More about ABEO
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.